Skip to content
Wired News Engine – Lifestyle
Author:
ALTERITY THERAPEUTICS LIMITED
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
August 12, 2026
Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference
August 6, 2026
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
July 30, 2026
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
July 21, 2026
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
July 7, 2026
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
June 9, 2026
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
May 19, 2026
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
May 11, 2026
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
May 7, 2026
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
April 30, 2026
1
2
Next Page
→